Janssen's vaccine, which has the effect of preventing Corona 19 even if it is hit once, has been officially licensed in Korea.



It is the third corona 19 vaccine licensed in Korea after AstraZeneca and Pfizer.



The Ministry of Food and Drug Safety held a final inspection committee including external experts today (7th) and decided to approve Janssen's COVID-19 vaccine'Covid-19 vaccine Jansenju'.



The Ministry of Food and Drug Safety decided in this way through a'triple' consultation process, but instead put a condition to submit the final report of clinical trials after approval.



This product is a viral vector vaccine developed by Janssen, the pharmaceutical division of Johnson & Johnson, a multinational pharmaceutical company, and Janssen, Korea officially applied for an import item license from the Ministry of Food and Drug Safety in February.



Covid-19 Vaccine Jansenju is the only one-time vaccination product among corona 19 vaccines that have been confirmed to be introduced in Korea, and can be stored for 24 months at minus 25 to 15°C.



According to the final review committee, Janssen's COVID-19 vaccine clinical trial result showed that the preventive effect was acceptable at 66.9% after 14 days of vaccination and 66.1% after 28 days, and it was concluded that the overall safety was also good.



Common abnormal cases were pain at the injection site, headache, fatigue, and muscle pain, which recovered within 2 to 3 days after vaccination.



The final inspection committee is generally safe, but after approval, through a risk management plan, the safety of tinnitus and cerebral sinus thrombosis is continuously observed and abnormal cases are collected and evaluated.



The Ministry of Food and Drug Safety announced that even after the Janssen Corona 19 vaccine was approved, it would cooperate with the Korea Centers for Disease Control and Prevention to strengthen the surveillance system for abnormal cases after vaccination and to thoroughly monitor it.



The government signed a purchase contract with Janssen for 6 million vaccines, and the domestic introduction schedule is under discussion.



(Photo = Getty Image Korea)